Cargando…

Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers

In our article, we evaluated the regulatory effects of the infusions of rituximab, a monoclonal antibody directed against CD20(+) B cells, on the serum matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) levels in patients with active rheumatoid arthritis (RA) not...

Descripción completa

Detalles Bibliográficos
Autores principales: Klimiuk, Piotr Adrian, Domysławska, Izabela, Sierakowski, Stanisław, Chwiećko, Justyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365285/
https://www.ncbi.nlm.nih.gov/pubmed/25190551
http://dx.doi.org/10.1007/s00296-014-3112-1
_version_ 1782362196630568960
author Klimiuk, Piotr Adrian
Domysławska, Izabela
Sierakowski, Stanisław
Chwiećko, Justyna
author_facet Klimiuk, Piotr Adrian
Domysławska, Izabela
Sierakowski, Stanisław
Chwiećko, Justyna
author_sort Klimiuk, Piotr Adrian
collection PubMed
description In our article, we evaluated the regulatory effects of the infusions of rituximab, a monoclonal antibody directed against CD20(+) B cells, on the serum matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) levels in patients with active rheumatoid arthritis (RA) not responding to anti-tumor necrosis factor (anti-TNF) therapy. Twelve RA patients were planned to receive four infusions of 1,000 mg of rituximab at weeks 0, 2, 24 and 26. The therapy was combined with methotrexate (MTX) (20–30 mg/week). Seven patients were refractory to previously received infliximab, and five to etanercept. Serum concentrations of interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), gelatinase B (MMP-9) and TIMP-1 were measured by ELISA on weeks 0, 2, 12, 24, 36 and 52. Initial infusion of rituximab downregulated serum MMP-1 (p < 0.01), MMP-3 (p < 0.001), MMP-9 (p < 0.001) and TIMP-1 (p < 0.05) levels. Second drug administration caused even more remarkable reduction of measured MMPs (p < 0.001 in all cases) and TIMP-1 level (p < 0.01). These findings were accompanied by significantly decreased ratios of measured MMPs to TIMP-1. Next rituximab infusions on weeks 24 and 26 sustained the suppression of serum MMPs levels. Prior to the initial rituximab infusion, serum concentrations of studied MMPs and TIMP-1 significantly correlated with markers of RA activity such as disease activity score (DAS28) and CRP levels. Rituximab therapy, beside a rapid clinical improvement, reduced serum MMPs concentrations in RA patients refractory to anti-TNF treatment. Repeated infusions of rituximab maintained initial serum MMPs suppression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00296-014-3112-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4365285
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-43652852015-03-26 Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers Klimiuk, Piotr Adrian Domysławska, Izabela Sierakowski, Stanisław Chwiećko, Justyna Rheumatol Int Original Article - Emerging Hypotheses In our article, we evaluated the regulatory effects of the infusions of rituximab, a monoclonal antibody directed against CD20(+) B cells, on the serum matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) levels in patients with active rheumatoid arthritis (RA) not responding to anti-tumor necrosis factor (anti-TNF) therapy. Twelve RA patients were planned to receive four infusions of 1,000 mg of rituximab at weeks 0, 2, 24 and 26. The therapy was combined with methotrexate (MTX) (20–30 mg/week). Seven patients were refractory to previously received infliximab, and five to etanercept. Serum concentrations of interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), gelatinase B (MMP-9) and TIMP-1 were measured by ELISA on weeks 0, 2, 12, 24, 36 and 52. Initial infusion of rituximab downregulated serum MMP-1 (p < 0.01), MMP-3 (p < 0.001), MMP-9 (p < 0.001) and TIMP-1 (p < 0.05) levels. Second drug administration caused even more remarkable reduction of measured MMPs (p < 0.001 in all cases) and TIMP-1 level (p < 0.01). These findings were accompanied by significantly decreased ratios of measured MMPs to TIMP-1. Next rituximab infusions on weeks 24 and 26 sustained the suppression of serum MMPs levels. Prior to the initial rituximab infusion, serum concentrations of studied MMPs and TIMP-1 significantly correlated with markers of RA activity such as disease activity score (DAS28) and CRP levels. Rituximab therapy, beside a rapid clinical improvement, reduced serum MMPs concentrations in RA patients refractory to anti-TNF treatment. Repeated infusions of rituximab maintained initial serum MMPs suppression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00296-014-3112-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2014-09-05 2015 /pmc/articles/PMC4365285/ /pubmed/25190551 http://dx.doi.org/10.1007/s00296-014-3112-1 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article - Emerging Hypotheses
Klimiuk, Piotr Adrian
Domysławska, Izabela
Sierakowski, Stanisław
Chwiećko, Justyna
Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers
title Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers
title_full Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers
title_fullStr Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers
title_full_unstemmed Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers
title_short Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers
title_sort regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers
topic Original Article - Emerging Hypotheses
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365285/
https://www.ncbi.nlm.nih.gov/pubmed/25190551
http://dx.doi.org/10.1007/s00296-014-3112-1
work_keys_str_mv AT klimiukpiotradrian regulationofserummatrixmetalloproteinasesandtissueinhibitorofmetalloproteinases1followingrituximabtherapyinpatientswithrheumatoidarthritisrefractorytoantitumornecrosisfactorblockers
AT domysławskaizabela regulationofserummatrixmetalloproteinasesandtissueinhibitorofmetalloproteinases1followingrituximabtherapyinpatientswithrheumatoidarthritisrefractorytoantitumornecrosisfactorblockers
AT sierakowskistanisław regulationofserummatrixmetalloproteinasesandtissueinhibitorofmetalloproteinases1followingrituximabtherapyinpatientswithrheumatoidarthritisrefractorytoantitumornecrosisfactorblockers
AT chwieckojustyna regulationofserummatrixmetalloproteinasesandtissueinhibitorofmetalloproteinases1followingrituximabtherapyinpatientswithrheumatoidarthritisrefractorytoantitumornecrosisfactorblockers